BIEL IS THE DEFINITION OF AN UNDERVALUED ASSET
The current price reflects a world where almost no one is allowed to buy.
The future price will reflect a world where everyone can.
There is a massive story developing behind the scenes with BIEL that the daily charts simply cannot show yet. While most investors are focused on clinical data, the canine arthritis market, and the company’s operational cleanup, a far bigger force is quietly building: a global liquidity dam created by regulatory lockouts and the absence of audited financials. This is the kind of setup that doesn’t move a stock gradually—it re-rates it.
The Global “Lockout”
Right now, thousands of overseas shareholders—many of whom actively use the products—are unable to buy more shares.
They have the funds.
They have the brokerages.
They have the enthusiasm.
But they do not have the “Buy” button.
Because BIEL is still “Pink Limited,” international compliance filters and SEC Rule 15c2‑11 have removed purchase access for millions of retail investors outside the U.S. (and even many inside).
This isn’t a lack of demand.
It’s a regulatory chokehold.
The “8 Billion” Catalyst
When you consider the global population, the potential audience is enormous.
Billions of people currently cannot buy BIEL—not because of the product, but because of the reporting status.
The moment BIEL becomes Pink Current with audited financials, the automated compliance blocks at international brokerages begin to fall like dominoes.
And here’s the key:
These investors haven’t been able to buy for years—meaning there are almost no sellers among them. This is pure, one‑sided demand waiting to hit the market.
Audited Financials Are the Trigger
Audited financials don’t just satisfy OTC requirements—they unlock entire categories of buyers:
1. International Retail Investors
Most global brokerages require audited financials before allowing trading in U.S. OTC securities.
No audits = no access.
Audits = instant access.
2. U.S. Investors Who Only Buy Current, Audited Companies
There is a massive segment of U.S. retail and small institutional investors who will not touch unaudited companies. Audits flip that switch.
3. Compliance Algorithms
Brokerage risk filters are automated. The moment BIEL becomes current and audited, the restrictions lift without human intervention.
This is why the “Coiled Spring” metaphor is accurate:
You have years of pent‑up demand with almost zero offsetting supply.
The Hidden Engine: $40M+ in Tax‑Loss Carryforwards
While the regulatory unlock is the catalyst, the tax‑loss carryforwards are the engine that can power BIEL’s profitability for years.
The Estimated Tax Shield
Based on historical filings and 2025/2026 trends, BIEL’s accumulated deficit and Net Operating Losses (NOLs) are estimated at:
Over $40 million in tax‑free profit potential
This means the company can earn its first $40M+ in cumulative net profit without paying federal corporate income tax.
That is not a small advantage—it is a structural financial weapon.
Why This Matters Even More Now: The Royalty Pivot
BIEL’s shift toward an IP‑based royalty model fundamentally changes the economics:
Traditional Device Sales
<50% gross margin
Manufacturing, storage, shipping, labor, inventory risk
Royalty Model
90%+ margins
No manufacturing, No inventory, No logistics
Nearly pure profit!
And because of the NOLs:
Every $1M in royalty profit saves about $210,000 in taxes.
That cash stays in the company—fuel for growth, trials, or even share reduction.
The Math: A Simple Example
Assume BIEL reaches $5M in annual royalty revenue:
Overhead: $1M (very conservative)
Pre‑tax profit: $4M
Federal tax owed: $0 (shielded by NOLs)
That $4M stays on the balance sheet.
This is how small companies become financially self‑sustaining.
Why the Market Hasn’t Priced This In
Because the market can’t.
Until BIEL is Pink Current with audited financials, the majority of global buyers are locked out, and U.S. investors who require audits won’t touch it. The stock is being valued by a tiny fraction of its potential investor base.
This is the definition of a mispriced asset.
The Bottom Line: The Gate Is About to Open
When BIEL becomes current and audited, three things happen simultaneously:
1. Global buying pressure floods in
Millions of investors regain access—many of whom have been unable to buy for years.
2. U.S. audit‑only investors enter the market
A whole new category of buyers becomes eligible.
3. The $40M tax shield becomes real
Audited financials validate the NOLs, making the tax‑free profit runway visible to the market.
This Isn’t Just a Regulatory Update—It’s a Re‑Rating Event
BIEL has:
A product that works (ActiPatch, RecoveryRx)
A new high‑growth market (veterinary/canine)
A global shareholder base eager to buy
A royalty model with 90%+ margins
A $40M tax shield
A board being upgraded with top‑tier talent
A reporting status on the verge of unlocking global liquidity
The current price reflects a world where almost no one is allowed to buy.
The future price will reflect a world where everyone can.
The current price reflects a world where almost no one is allowed to buy.
The future price will reflect a world where everyone can.
There is a massive story developing behind the scenes with BIEL that the daily charts simply cannot show yet. While most investors are focused on clinical data, the canine arthritis market, and the company’s operational cleanup, a far bigger force is quietly building: a global liquidity dam created by regulatory lockouts and the absence of audited financials. This is the kind of setup that doesn’t move a stock gradually—it re-rates it.
The Global “Lockout”
Right now, thousands of overseas shareholders—many of whom actively use the products—are unable to buy more shares.
They have the funds.
They have the brokerages.
They have the enthusiasm.
But they do not have the “Buy” button.
Because BIEL is still “Pink Limited,” international compliance filters and SEC Rule 15c2‑11 have removed purchase access for millions of retail investors outside the U.S. (and even many inside).
This isn’t a lack of demand.
It’s a regulatory chokehold.
The “8 Billion” Catalyst
When you consider the global population, the potential audience is enormous.
Billions of people currently cannot buy BIEL—not because of the product, but because of the reporting status.
The moment BIEL becomes Pink Current with audited financials, the automated compliance blocks at international brokerages begin to fall like dominoes.
And here’s the key:
These investors haven’t been able to buy for years—meaning there are almost no sellers among them. This is pure, one‑sided demand waiting to hit the market.
Audited Financials Are the Trigger
Audited financials don’t just satisfy OTC requirements—they unlock entire categories of buyers:
1. International Retail Investors
Most global brokerages require audited financials before allowing trading in U.S. OTC securities.
No audits = no access.
Audits = instant access.
2. U.S. Investors Who Only Buy Current, Audited Companies
There is a massive segment of U.S. retail and small institutional investors who will not touch unaudited companies. Audits flip that switch.
3. Compliance Algorithms
Brokerage risk filters are automated. The moment BIEL becomes current and audited, the restrictions lift without human intervention.
This is why the “Coiled Spring” metaphor is accurate:
You have years of pent‑up demand with almost zero offsetting supply.
The Hidden Engine: $40M+ in Tax‑Loss Carryforwards
While the regulatory unlock is the catalyst, the tax‑loss carryforwards are the engine that can power BIEL’s profitability for years.
The Estimated Tax Shield
Based on historical filings and 2025/2026 trends, BIEL’s accumulated deficit and Net Operating Losses (NOLs) are estimated at:
Over $40 million in tax‑free profit potential
This means the company can earn its first $40M+ in cumulative net profit without paying federal corporate income tax.
That is not a small advantage—it is a structural financial weapon.
Why This Matters Even More Now: The Royalty Pivot
BIEL’s shift toward an IP‑based royalty model fundamentally changes the economics:
Traditional Device Sales
<50% gross margin
Manufacturing, storage, shipping, labor, inventory risk
Royalty Model
90%+ margins
No manufacturing, No inventory, No logistics
Nearly pure profit!
And because of the NOLs:
Every $1M in royalty profit saves about $210,000 in taxes.
That cash stays in the company—fuel for growth, trials, or even share reduction.
The Math: A Simple Example
Assume BIEL reaches $5M in annual royalty revenue:
Overhead: $1M (very conservative)
Pre‑tax profit: $4M
Federal tax owed: $0 (shielded by NOLs)
That $4M stays on the balance sheet.
This is how small companies become financially self‑sustaining.
Why the Market Hasn’t Priced This In
Because the market can’t.
Until BIEL is Pink Current with audited financials, the majority of global buyers are locked out, and U.S. investors who require audits won’t touch it. The stock is being valued by a tiny fraction of its potential investor base.
This is the definition of a mispriced asset.
The Bottom Line: The Gate Is About to Open
When BIEL becomes current and audited, three things happen simultaneously:
1. Global buying pressure floods in
Millions of investors regain access—many of whom have been unable to buy for years.
2. U.S. audit‑only investors enter the market
A whole new category of buyers becomes eligible.
3. The $40M tax shield becomes real
Audited financials validate the NOLs, making the tax‑free profit runway visible to the market.
This Isn’t Just a Regulatory Update—It’s a Re‑Rating Event
BIEL has:
A product that works (ActiPatch, RecoveryRx)
A new high‑growth market (veterinary/canine)
A global shareholder base eager to buy
A royalty model with 90%+ margins
A $40M tax shield
A board being upgraded with top‑tier talent
A reporting status on the verge of unlocking global liquidity
The current price reflects a world where almost no one is allowed to buy.
The future price will reflect a world where everyone can.
2
